Skip to content
Triangle logo TriangleGet started
← Study library

NCT00520130 · REGISTRY CONDITION SEARCH

Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase
PHASE1, PHASE2
Status at capture
COMPLETED
Registry last update
2019-03-05

Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD), a serious side effects of immune-suppressing chemotherapy that is given to bring the cancer under control before SCT. In GVHD, the patients immune system attacks the transplanted donor cells. This study will try to improve the results of SCT from unrelated HLA-matched donors using targeted immune-depleting chemotherapy to bring the cancer under control before transplantation and to lower the chance of graft rejection, followed by reduced-intensity transplant chemotherapy to make the procedure less toxic. Objectives: To evaluate the safety and effectiveness of targeted immune-depleting chemotherapy followed by reduced-intensity transplant chemotherapy in patients with advanced cancers of the blood and immune system. To evaluate the safety and effectiveness of two different drug combinations to prevent GVHD. Both regimens have been successful in preventing GVHD, but they work by different mechanisms and affect the rebuilding of the immune system after the transplant. Eligibility: People 18 to 74 years of age with advanced or high-risk cancers of the blood and immune system who do not have a suitable HLA-matched sibling. Design: All patients receive chemotherapy before transplant to treat the cancer and suppress immune function. All patients receive a conditioning regimen of cyclophosphamide for 4 days and fludarabine for 4 days before SCT to prepare for the transplant. Patients are randomly assigned to one of two combination drug treatments to prevent GHVD as follows: * Group 1: Tacrolimus starting 3 days before SCT and continuing for 6 months, plus methotrexate on days 1, 3, 6, and 11 post-SCT, plus sirolimus starting 3 days before the SCT and continues for 6 months following SCT. * Group 2: Alemtuzumab for 4 days starting 8 days before SCT, plus cyclosporine starting 1 day before SCT and continuing for 6 months. Patients receive the donors stem cells and immune cells 2 days after completing the conditioning regimen. Patients are followed at the clinic regularly for the first 6 months after SCT, and then less often for at least 5 years. Some visits may include bone marrow aspirates and biopsies, blood draws, and other tests to monitor disease status. A skin biopsy, oral mucosa biopsy, and saliva collection are done to study chronic GVHD. ...

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)

→

outcome · POSTED

Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells

→

outcome · POSTED

Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells

→

outcome · POSTED

Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire

→

outcome · POSTED

Changes in CD8 T Cell Receptor Vbeta Repertoire

→

outcome · POSTED

Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)

→

outcome · POSTED

Toxicities

→

outcome · POSTED

Days to Engraftment of Neutrophils

→

outcome · POSTED

Days to Engraftment of Platelets

→

outcome · POSTED

Days to Engraftment of Lymphocytes

→

outcome · POSTED

Overall Survival

→

outcome · POSTED

Early Treatment Related Mortality

→

outcome · POSTED

Percentage of Participants With Late Treatment Related Mortality

→

outcome · POSTED

Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant

→

outcome · POSTED

Immune Reconstitution of Normal Killer (NK) Cells

→

outcome · POSTED

Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations

→

outcome · POSTED

Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→
Who could take part
eligibility Criteria
* ELIGIBILITY CRITERIA RECIPIENT ON STANDARD CARE THERAPY: * The patient is 18-74 years of age. * The patient has a potentially suitable 8/8 donor if they are between the ages of 69-74 years of age or a potentially suitable 8/8 or 7/8 unrelated donor(s) in the National Marrow Registry or Other Available Registry if they are between the ages of 18-74. * The patient currently does not meet the protocol s eligibility/enrollment criteria for any reason. * There is a high likelihood that the patient, in the opinion of the principal investigator (PI) or lead associate investigator (LAI), will meet the protocols eligibility/enrollment criteria to proceed to transplant after standard therapy is completed. * The patient or legal guardian is able to give informed consent. EXCLUSION CRITERIA RECIPIENT ON STANDARD CARE THERAPY: * Human immunodeficiency virus (HIV) infection. There is theoretical concern that the degree of immune suppression associated with the treatment may result in progression of HIV infection. * Pregnant or lactating. Patients of childbearing potential must use an effective method of contraception. The effects of the chemotherapy, the subsequent transplant and the medications used after the transplant are highly likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to the infant.
healthy Volunteers
false
maximum Age
74 Years
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    TMS Arm
    intervention Names
    1. Biological: Rituximab
    2. Drug: Allogenic stem cell transplant (ASCT)
    3. Drug: Conditioning Chemotherapy
    4. Drug: TMS
    5. Drug: FLAG
    6. Drug: EPOCH-F
    label
    A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    type
    EXPERIMENTAL
  2. description
    AC Arm
    intervention Names
    1. Biological: Rituximab
    2. Drug: Cyclosporine
    3. Drug: Allogenic stem cell transplant (ASCT)
    4. Drug: Conditioning Chemotherapy
    5. Drug: FLAG
    6. Drug: EPOCH-F
    7. Biological: Alemtuzumab
    label
    B - Cyclosporine (AC) Arm
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    2. B - Cyclosporine (AC) Arm
    description
    Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
    name
    Rituximab
    other Names
    1. Rituxan
    type
    BIOLOGICAL
  2. arm Group Labels
    1. B - Cyclosporine (AC) Arm
    description
    Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
    name
    Cyclosporine
    other Names
    1. Neoral
    type
    DRUG
  3. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    2. B - Cyclosporine (AC) Arm
    description
    Allogenic stem cell transplant
    name
    Allogenic stem cell transplant (ASCT)
    type
    DRUG
  4. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    2. B - Cyclosporine (AC) Arm
    description
    Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3. Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3
    name
    Conditioning Chemotherapy
    type
    DRUG
  5. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    description
    Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
    name
    TMS
    other Names
    1. Prograf
    type
    DRUG
  6. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    2. B - Cyclosporine (AC) Arm
    description
    Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
    name
    FLAG
    other Names
    1. Fludarabine+high-dose cytarabine+G-CSF (Filgrastim))
    type
    DRUG
  7. arm Group Labels
    1. A - Tacrolimus, methotrexate, sirolimus (TMS) Arm
    2. B - Cyclosporine (AC) Arm
    description
    Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
    name
    EPOCH-F
    type
    DRUG
  8. arm Group Labels
    1. B - Cyclosporine (AC) Arm
    description
    Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
    name
    Alemtuzumab
    other Names
    1. Campath
    type
    BIOLOGICAL
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
92
type
ACTUAL
Registered outcome plans (not posted results)
primary Outcomes
  1. description
    Acute GVHD is assessed by the 1994 Consensus Conference on Acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria.
    measure
    Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)
    time Frame
    6 months
  2. description
    Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. First the individual organ scoring is done, and then based on that the Global score is determined (mild-moderate-severe). See Citation: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56., for grading criteria.
    measure
    Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)
    time Frame
    2 years post transplant
  3. description
    The percentage of C-C motif chemokine receptor 7 (CCR7)+CD45RA+ naïve T cells within the CD4 T cell populations was determined by flow cytometry.
    measure
    Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells
    time Frame
    Recipient recovery at 6, 12 and 24 months post transplant
  4. description
    The percentage of CCR7+CD45RA+ naïve T cells within the CD4 and CD8 T cell populations was determined by flow cytometry.
    measure
    Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells
    time Frame
    Recipient recovery at 6, 12 and 24 months post transplant
  5. description
    Ribonucleic acid (RNA) was extracted from sorted CD4 and cluster of differentiation 8 (CD8) T cells and analyzed for Vbeta repertoire by nested polymerase chain reaction (PCR) analysis using Vbeta family specific primers and a labeled constant region primer (spectratyping). The receptor repertoire diversity was calculated from spectratyping data by creating a normal standard for repertoire diversity from healthy normal controls and assessing the divergence of individual patient's T cell receptor repertoire from these standard normal donor values. In this Vbeta repertoire divergence index, lower numbers are consistent with a more normal highly diverse repertoire, and high numbers represent a highly skewed, oligoclonal repertoire. The assay is described in Memon SA et al, J Immunol Methods, 2012, 375: 84-92. The repertoire diversity of the CD4 and CD8 T cells of the donor infusion is shown for comparison.
    measure
    Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire
    time Frame
    Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant
  6. description
    Ribonucleic acid (RNA) was extracted from sorted CD4 and cluster of differentiation 8 (CD8) T cells and analyzed for Vbeta repertoire by nested polymerase chain reaction (PCR) analysis using Vbeta family specific primers and a labeled constant region primer (spectratyping). The receptor repertoire diversity was calculated from spectratyping data by creating a normal standard for repertoire diversity from healthy normal controls and assessing the divergence of individual patient's T cell receptor repertoire from these standard normal donor values. In this Vbeta repertoire divergence index, lower numbers are consistent with a more normal highly diverse repertoire, and high numbers represent a highly skewed, oligoclonal repertoire. The assay is described in Memon SA et al, J Immunol Methods, 2012, 375: 84-92. The repertoire diversity of the CD4 and CD8 T cells of the donor infusion is shown for comparison.
    measure
    Changes in CD8 T Cell Receptor Vbeta Repertoire
    time Frame
    Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant
secondary Outcomes
  1. description
    Acute GVHD is assessed by the 1994 Consensus Conference on acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria.
    measure
    Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)
    time Frame
    6 months
  2. description
    Here are the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.
    measure
    Toxicities
    time Frame
    103 months and 22 days
  3. description
    Days to engraftment is defined as neutrophil recovery: designated by the first of 3 consecutive days with an absolute neutrophil count (ANC) above 500/mm(3).
    measure
    Days to Engraftment of Neutrophils
    time Frame
    2 years
  4. description
    Platelet recovery: designated by the first of 7 days where the platelet count remains above 20,000/mm(3) without transfusion support
    measure
    Days to Engraftment of Platelets
    time Frame
    2 years
  5. description
    Lymphocyte recovery: designated by the first of 3 consecutive days with absolute lymphocyte count (ALC) above 500/mm(3).
    measure
    Days to Engraftment of Lymphocytes
    time Frame
    2 years
  6. description
    Time between the first day of transplant to the day of death.
    measure
    Overall Survival
    time Frame
    Patients were followed for an average of up to 5 years.
  7. description
    Any death occurring within 28 days after transplantation in a patient in continuous remission.
    measure
    Early Treatment Related Mortality
    time Frame
    Less than or equal to 28 days after transplantation
  8. description
    Any death occurring 28 days or more after transplantation in a patient in continuous remission.
    measure
    Percentage of Participants With Late Treatment Related Mortality
    time Frame
    Greater than 28 days after transplantation
  9. description
    During depletion of lymphocytes during transplant conditioning, levels of homeostatic cytokines increase in the blood. These then decline with the expansion of new donor-derived cells. The rapidity of decline may predict acute graft versus host disease (AGVHD). Decline in cytokine IL-7 will be assessed by the enzyme-linked immunosorbent assay (ELISA).
    measure
    Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant
    time Frame
    Day 0, 1 week and 2 weeks
  10. description
    Cluster of differentiation 3 (CD3) - cluster of differentiation 56 (CD56) + Natural Killer (NK) cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.
    measure
    Immune Reconstitution of Normal Killer (NK) Cells
    time Frame
    2 weeks, and 1, 3, 6, 12, and 24 months post transplant
  11. description
    Cluster of Differentiation 3 (CD3)+CD4+ and CD3+Cluster of Differentiation 8 (CD8)+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.
    measure
    Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations
    time Frame
    2 weeks, and 1, 3, 6, 12 and 24 months post transplant
  12. description
    Cluster of differentiation 3 (CD3)+cluster of differentiation 4 (CD4)+ and CD3+CD8+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.
    measure
    Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations
    time Frame
    2 weeks, 1, 3, 6, 12 and 24 months post transplant
Full study description
brief Summary
Background: Major problems with stem cell transplantation (SCT) for cancer treatment are a lack of suitable donors for patients without a human leukocyte-antigen (HLA) tissue-matched sibling and graft-versus-host disease (GVHD), a serious side effects of immune-suppressing chemotherapy that is given to bring the cancer under control before SCT. In GVHD, the patients immune system attacks the transplanted donor cells. This study will try to improve the results of SCT from unrelated HLA-matched donors using targeted immune-depleting chemotherapy to bring the cancer under control before transplantation and to lower the chance of graft rejection, followed by reduced-intensity transplant chemotherapy to make the procedure less toxic. Objectives: To evaluate the safety and effectiveness of targeted immune-depleting chemotherapy followed by reduced-intensity transplant chemotherapy in patients with advanced cancers of the blood and immune system. To evaluate the safety and effectiveness of two different drug combinations to prevent GVHD. Both regimens have been successful in preventing GVHD, but they work by different mechanisms and affect the rebuilding of the immune system after the transplant. Eligibility: People 18 to 74 years of age with advanced or high-risk cancers of the blood and immune system who do not have a suitable HLA-matched sibling. Design: All patients receive chemotherapy before transplant to treat the cancer and suppress immune function. All patients receive a conditioning regimen of cyclophosphamide for 4 days and fludarabine for 4 days before SCT to prepare for the transplant. Patients are randomly assigned to one of two combination drug treatments to prevent GHVD as follows: * Group 1: Tacrolimus starting 3 days before SCT and continuing for 6 months, plus methotrexate on days 1, 3, 6, and 11 post-SCT, plus sirolimus starting 3 days before the SCT and continues for 6 months following SCT. * Group 2: Alemtuzumab for 4 days starting 8 days before SCT, plus cyclosporine starting 1 day before SCT and continuing for 6 months. Patients receive the donors stem cells and immune cells 2 days after completing the conditioning regimen. Patients are followed at the clinic regularly for the first 6 months after SCT, and then less often for at least 5 years. Some visits may include bone marrow aspirates and biopsies, blood draws, and other tests to monitor disease status. A skin biopsy, oral mucosa biopsy, and saliva collection are done to study chronic GVHD. ...
detailed Description
Background: * The major limitations to the broader applicability of allogeneic hematopoietic stem cell transplantation (HSCT) for the treatment of malignancies are lack of suitable donors and therapy-related toxicities which include delayed and incomplete immune reconstitution and graft-versus-host disease (GVHD). Based on the theory that the rapid establishment of donor chimerism was essential for an optimal graft-versus-tumor effect, we have employed a strategy of targeted immune depleting chemotherapy prior to reduced-intensity allogeneic HSCT. It is our intent to investigate this approach in the setting of human leukocyte-antigen (HLA)-matched unrelated donors in a pilot manner. * A clearly superior GVHD prophylaxis regimen has not been established in the unrelated donor transplant setting. The best results that have been reported are with the combination of alemtuzumab plus cyclosporine \[AC\] and the combination of tacrolimus, methotrexate, and sirolimus \[TMS\]. These two regimens work by mechanisms which are biologically distinct and potentially have markedly different effects upon immune reconstitution that have not been well studied. In addition, neither of these regimens has been assessed for their effects on chronic GVHD using the National Institutes of Health (NIH) Consensus Conference Criteria. It is our intent to study the effects that these two regimens have on immune reconstitution and chronic GVHD in the setting sequential targeted immune-depleting chemotherapy and reduced-intensity allogeneic HSCT from HLA-matched unrelated donors. Objectives: * Primary objectives: 1. to assess the effects of two biologically distinct GVHD prophylaxis regimens, TMS and AC, on immune reconstitution in patients receiving targeted-immune depletion and reduced-intensity allogeneic HSCT from HLA-matched unrelated donors. As part of a comprehensive assessment of immune reconstitution, the primary immunologic endpoint will be the determination of cluster of differentiation 4 (CD4)+ T cell receptor V BETA repertoire by complementarity determining region 3 (CDR3) spectratyping at 3 months post-transplant. 2. to assess overall safety of these two regimens in this setting, as determined by engraftment, acute GVHD, early and late treatment-related mortality, and overall survival. 3. to determine and monitor incidence, organ severity and overall severity of chronic GVHD prospectively using the newly developed NIH Consensus Conference diagnosis and staging criteria and preliminarily validate those tools for use in clinical practice and trials. * Secondary objectives include further assessment of immune reconstitution, study of engraftment kinetics, and assessment of those patients who receive higher doses of anthracyclines for long and short term toxicities Eligibility: * Adults (18-74 years) with advanced or high risk hematologic malignancies including acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL), myelodysplastic syndrome (MDS), chronic lymphocytic leukemia (CLL), non-hodgkin lymphoma (NHL), hodgkin lymphoma (HL), chronic myelogenous leukemia (CML), multiple myeloma, and myeloproliferative disorder (MPD) who lack a suitable HLA matched sibling. * An unrelated donor matched at a minimum of 7 of 8 alleles (HLA-A,-B,-C, and DRB1) by high resolution typing, identified through the National Marrow Donor Program. * Life expectancy of at least 3 months, Eastern Cooperative Oncology Group (ECOG) less than or equal to 2 and relatively normal major organ functions. Design: * Patients will receive disease-specific induction chemotherapy (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin (EPOCH-fludarabine (F)/rituximab (R) or fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG)) prior to transplant for disease control and immune depletion. If disease is controlled (greater than partial response (PR)) and immune depletion objectives have been met, patients may forgo induction chemotherapy and move forward to the transplant conditioning regimen. * All patients will receive an identical conditioning regimen consisting of cyclophosphamide 1200 mg/m(2)/day intravenous (IV) for 4 days and fludarabine 30 mg/m(2)/day for 4 days. * Patients will be stratified according to degree of HLA-match and randomized at the time of enrollment to one of two GHVD prophylaxis regimens: * Group 1: Tacrolimus starting 3 days before stem cell transplant (SCT), and continuing for 6 months, plus methotrexate on days 1, 3, 6, and 11 post-SCT, plus sirolimus starting 3 days before the SCT and continues for 6 months following SCT. * Group 2: Alemtuzumab for 4 days starting 8 days before SCT, plus cyclosporine starting 1 day before SCT and continuing for 6 months. * A maximum of 105 patients will be enrolled and randomly assigned to the two arms in order to yield 44 patients per arm (88 total patients) who are able to be evaluated for development of severe chronic GVHD.
Source references
references
  1. citation
    Pavletic SZ, Martin P, Lee SJ, Mitchell S, Jacobsohn D, Cowen EW, Turner ML, Akpek G, Gilman A, McDonald G, Schubert M, Berger A, Bross P, Chien JW, Couriel D, Dunn JP, Fall-Dickson J, Farrell A, Flowers ME, Greinix H, Hirschfeld S, Gerber L, Kim S, Knobler R, Lachenbruch PA, Miller FW, Mittleman B, Papadopoulos E, Parsons SK, Przepiorka D, Robinson M, Ward M, Reeve B, Rider LG, Shulman H, Schultz KR, Weisdorf D, Vogelsang GB; Response Criteria Working Group. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66. doi: 10.1016/j.bbmt.2006.01.008.
    pmid
    16503494
    type
    BACKGROUND
  2. citation
    Shaffer BC, Modric M, Stetler-Stevenson M, Arthur DC, Steinberg SM, Liewehr DJ, Fowler DH, Gale RP, Bishop MR, Pavletic SZ. Rapid complete donor lymphoid chimerism and graft-versus-leukemia effect are important in early control of chronic lymphocytic leukemia. Exp Hematol. 2013 Sep;41(9):772-8. doi: 10.1016/j.exphem.2013.04.015. Epub 2013 May 18.
    pmid
    23689118
    type
    BACKGROUND
  3. citation
    Pavletic SZ, Lee SJ, Socie G, Vogelsang G. Chronic graft-versus-host disease: implications of the National Institutes of Health consensus development project on criteria for clinical trials. Bone Marrow Transplant. 2006 Nov;38(10):645-51. doi: 10.1038/sj.bmt.1705490. Epub 2006 Sep 18.
    pmid
    16980994
    type
    BACKGROUND
  4. citation
    Hardy NM, Fellowes V, Rose JJ, Odom J, Pittaluga S, Steinberg SM, Blacklock-Schuver B, Avila DN, Memon S, Kurlander RJ, Khuu HM, Stetler-Stevenson M, Mena E, Dwyer AJ, Levine BL, June CH, Reshef R, Vonderheide RH, Gress RE, Fowler DH, Hakim FT, Bishop MR. Costimulated tumor-infiltrating lymphocytes are a feasible and safe alternative donor cell therapy for relapse after allogeneic stem cell transplantation. Blood. 2012 Mar 22;119(12):2956-9. doi: 10.1182/blood-2011-09-378398. Epub 2012 Jan 30.
    pmid
    22289893
    type
    BACKGROUND
  5. citation
    Holtzman NG, Curtis LM, Salit RB, Shaffer BC, Pirsl F, Ostojic A, Steinberg SM, Schulz E, Wilder JS, Hughes TE, Rose J, Memon S, Korngold R, Gea-Banacloche JC, Fowler DH, Hakim FT, Gress RE, Bishop MR, Pavletic SZ. High-dose alemtuzumab and cyclosporine vs tacrolimus, methotrexate, and sirolimus for chronic graft-versus-host disease prevention. Blood Adv. 2024 Aug 27;8(16):4294-4310. doi: 10.1182/bloodadvances.2023010973.
    pmid
    38669315
    type
    DERIVED
  6. citation
    Assmann JC, Farthing DE, Saito K, Maglakelidze N, Oliver B, Warrick KA, Sourbier C, Ricketts CJ, Meyer TJ, Pavletic SZ, Linehan WM, Krishna MC, Gress RE, Buxbaum NP. Glycolytic metabolism of pathogenic T cells enables early detection of GVHD by 13C-MRI. Blood. 2021 Jan 7;137(1):126-137. doi: 10.1182/blood.2020005770.
    pmid
    32785680
    type
    DERIVED
see Also Links
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-1336d216cbd1bbff780dac70
      edge id
      nct-edge-07a90006bc1fdcdce3d3
      requested nct id
      NCT00520130
      primary nct id
      NCT00520130
      source kind
      ctgov_condition_query
      source record id
      Source null
      source file sha256
      f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
      payload sha256
      42c69f80d92a05c334ea97c9bd17944eb80abadb2c15ac91469e9d27d856a9ba
      payload
      clinical indication matching status
      condition_index_match_asserted_by_registry_not_reviewed
      end exclusive
      true
      id
      nct-edge-07a90006bc1fdcdce3d3
      link basis
      returned_by_explicit_condition_and_posted_results_filter_query
      nct id
      NCT00520130
      occurrences
      1. context exact
        NCT00520130
        end
        11
        exact text
        NCT00520130
        start
        0
      offset unit
      unicode_code_points
      query cond
      Plasma Cell Neoplasms
      query disease state id
      ds-plasma-cell-neoplasms
      source file
      /Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-001.json
      source file sha256
      f61b5b8281f834a98709317598003056a2aa82c9b92a292e3623f400c9c3291b
      source json pointer
      /studies/63/protocolSection/identificationModule/nctId
      source kind
      ctgov_condition_query
      source record id
      Source null
      source string basis
      parsed_JSON_string_unmodified
      source string sha256
      f00deff74edaa28afaaac3721e150948d371797ffb66f852b40e3e1e568786f6

    Preserved source evidence · Not medical advice